{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:05:38Z","timestamp":1790301938540,"version":"4.1.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Conventional treatment techniques have limited efficacy and more side effects in the treatment of prurigo nodularis. The better alternative treatment option for better outcomes of the disease is dupilumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The objective of this study was to systematically review dupilumab-related treatment outcomes in prurigo nodularis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Several databases like Embase, PubMed, Web of Science, and Cochrane library were searched for data acquisition on October 8, 2022. Based on Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, 24 publications were included in this study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After 4,12,16 and more than 16 weeks of dupilumab treatment, 8.3% (n=5\/60), 34.4% (n=11\/32), 3.6% (n=2\/56), and 45.3% (n=29\/64) of patients had complete remission, respectively. In addition, 85.0% (n=51\/60), 59.4% (n=19\/32), 83.9% (n=47\/56), and 43.8% (n=28\/64) had partial remission, respectively. Moreover, 6.7% (n=4\/60), 6.3% (n=2\/32), 12.5% (n=7\/56), and 10.9% (n=7\/64) showed no remission, respectively, and significant reduction of numeric rating scale itch intensity (from 9.0 to 4.9, 2.1, 2.8, 0.9) was attained. There were no serious adverse events observed during treatment, but the most common event observed was conjunctivitis (12.6%, n=15\/119).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Dupilumab has definite effectiveness and safety in prurigo nodularis treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO<\/jats:uri>, identifier (CRD42022365802).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1092685","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T06:44:43Z","timestamp":1674197083000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Dupilumab for the treatment of prurigo nodularis: A systematic review"],"prefix":"10.3389","volume":"14","author":[{"given":"Peng","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamadermatol.2021.5307","article-title":"Prurigo nodularis","volume":"158","author":"Kwatra","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","article-title":"Real-world prevalence of prurigo nodularis and burden of associated diseases","volume":"140","author":"Huang","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1916733","article-title":"Breaking the itch-scratch cycle in prurigo nodularis","volume":"382","author":"Kwatra","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.182","article-title":"Prurigo nodularis: Pathogenesis and management","volume":"83","author":"Williams","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14570","article-title":"European Academy of dermatology and venereology European prurigo project: Expert consensus on the definition, classification and terminology of chronic prurigo","volume":"32","author":"Pereira","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.07.022","article-title":"Diagnostic and treatment algorithm for chronic nodular prurigo","volume":"82","author":"Stander","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-Severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"B9","unstructured":"Dupixent\u00ae (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17046","article-title":"Our experience with prurigo nodularis treated with dupilumab","volume":"35","author":"Tilotta","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15957","article-title":"Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients","volume":"34","author":"Calugareanu","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jaad.2020.03.049","article-title":"Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo","volume":"83","author":"Chiricozzi","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.02.038","article-title":"Long-term dupilumab treatment for chronic refractory generalized prurigo nodularis: A retrospective cohort study","volume":"85","author":"Georgakopoulos","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000517","article-title":"Effectiveness of dupilumab for the treatment of generalized prurigo nodularis phenotype of adult atopic dermatitis","volume":"31","author":"Napolitano","year":"2020","journal-title":"Dermatitis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/medicines6030072","article-title":"Chronic pruritus responding to dupilumab-a case series","volume":"6","author":"Zhai","year":"2019","journal-title":"Medicines (Basel)."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.3912","article-title":"Dupilumab treatment for generalized prurigo nodularis","volume":"155","author":"Beck","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e13222","DOI":"10.1111\/dth.13222","article-title":"Dupilumab for prurigo nodularis: Case series and review of the literature","volume":"33","author":"Holm","year":"2020","journal-title":"Dermatol Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.3906","article-title":"Reduced itch associated with dupilumab treatment in 4 patients with prurigo nodularis","volume":"155","author":"Mollanazar","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.03.016","article-title":"Recalcitrant prurigo nodularis treated successfully with dupilumab","volume":"5","author":"Rambhia","year":"2019","journal-title":"JAAD Case Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e8737","DOI":"10.7759\/cureus.8737","article-title":"Resolution of treatment-refractory prurigo nodularis with dupilumab: A case series","volume":"12","author":"Wieser","year":"2020","journal-title":"Cureus"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.10.005","article-title":"Simultaneous treatment of samter triad and prurigo nodularis with dupilumab","volume":"18","author":"Bloomstein","year":"2021","journal-title":"JAAD Case Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15584","article-title":"Dramatic improvement of generalized prurigo nodularis with dupilumab","volume":"33","author":"Calugareanu","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14994","article-title":"Dupilumab as a useful treatment option for prurigo nodularis in an elderly patient with atopic diathesis","volume":"59","author":"Criado","year":"2020","journal-title":"Int J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.02.029","article-title":"Dupilumab: A safe and successful treatment in refractory prurigo nodularis","volume":"10","author":"Cunha","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14464","article-title":"Dupilumab for pediatric prurigo nodularis: A case report","volume":"38","author":"Fachler","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2020.3947","article-title":"Dupilumab treatment of prurigo nodularis in an adolescent","volume":"31","author":"Giovannini","year":"2021","journal-title":"Eur J Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e13201","DOI":"10.1111\/dth.13201","article-title":"Efficacy of dupilumab in prurigo nodularis in elderly patient","volume":"33","author":"Giura","year":"2020","journal-title":"Dermatol Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18445","article-title":"Ustekinumab plus dupilumab in the treatment of concomitant psoriasis and prurigo nodularis","volume":"36","author":"Kabbani","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14107","article-title":"Dupilumab for treatment-refractory prurigo nodularis","volume":"18","author":"Kovacs","year":"2020","journal-title":"J Dtsch Dermatol Ges."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S300975","article-title":"Effectiveness of dupilumab for an elderly patient with prurigo nodularis who was refractory and contradicted to traditional therapy","volume":"14","author":"Liu","year":"2021","journal-title":"J Asthma Allergy"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0550","article-title":"Safety and effectiveness of dupilumab in prurigo nodularis","volume":"31","author":"Romano","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3390\/brainsci12050605","article-title":"Post-stroke asymmetric prurigo nodularis responding to dupilumab treatment: A case report","volume":"12","author":"Sammarra","year":"2022","journal-title":"Brain Sci"},{"key":"B34","article-title":"Dupilumab treatment for prurigo nodularis and pruritis","volume":"18","author":"Tanis","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1853024","article-title":"Dupilumab in prurigo nodularis: A systematic review of current evidence and analysis of predictive factors to response","volume":"33","author":"Husein-ElAhmed","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10498.x","article-title":"Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis","volume":"165","author":"Fukushi","year":"2011","journal-title":"Br J Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons Co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1700366","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"376","author":"Simpson","year":"2017","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15914","article-title":"Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis","volume":"34","author":"Voorberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17538","article-title":"Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis","volume":"180","author":"Bakker","year":"2019","journal-title":"Br J Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15608","article-title":"Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion","volume":"33","author":"Thyssen","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16234","article-title":"Ocular surface disease during dupilumab treatment in patients with atopic dermatitis, is it possible to prevent it","volume":"34","author":"Pistone","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2049588","article-title":"Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease","volume":"33","author":"Ferrucci","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B44","doi-asserted-by":"publisher","first-page":"adv00625","DOI":"10.2340\/actadv.v101.224","article-title":"Successful treatment of atopic dermatitis with dupilumab in a patient with non-hodgkin's lymphoma","volume":"102","author":"Qiu","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"899","DOI":"10.2340\/00015555-3201","article-title":"Two cancer patients receiving dupilumab for treatment of atopic dermatitis","volume":"99","author":"Fowler","year":"2019","journal-title":"Acta Derm Venereol."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.5070\/D327854709","article-title":"Dupilumab in HIV-positive patients with atopic dermatitis: A long-term follow-up patient and a literature review","volume":"27","author":"Avallone","year":"2021","journal-title":"Dermatol Online J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1092685\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T06:44:50Z","timestamp":1674197090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1092685\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2023.1092685"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1092685","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"article-number":"1092685"}}